Benchmark Competitors

Benchmark (LON:BMK) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Earnings and Valuation

This table compares Benchmark and PureTech Health's revenue, earnings per share and valuation.

Benchmark is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Benchmark and PureTech Health's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Benchmark and PureTech Health, as reported by MarketBeat.com.

PureTech Health has a consensus price target of GBX 481.25, indicating a potential upside of 19.27%. Given PureTech Health's higher possible upside, analysts clearly believe PureTech Health is more favorable than Benchmark.

Summary

PureTech Health beats Benchmark on 5 of the 6 factors compared between the two stocks.

Benchmark (LON:BMK) and Clinigen Group (LON:CLIN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Benchmark and Clinigen Group's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Benchmark and Clinigen Group, as reported by MarketBeat.com.

Clinigen Group has a consensus price target of GBX 997.50, suggesting a potential upside of 18.05%. Given Clinigen Group's higher possible upside, analysts clearly believe Clinigen Group is more favorable than Benchmark.

Earnings and Valuation

This table compares Benchmark and Clinigen Group's gross revenue, earnings per share (EPS) and valuation.

Benchmark is trading at a lower price-to-earnings ratio than Clinigen Group, indicating that it is currently the more affordable of the two stocks.

Summary

Clinigen Group beats Benchmark on 5 of the 6 factors compared between the two stocks.

Indivior (LON:INDV) and Benchmark (LON:BMK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Indivior and Benchmark, as reported by MarketBeat.

Indivior currently has a consensus price target of GBX 195, suggesting a potential upside of 46.40%. Given Indivior's higher possible upside, equities analysts plainly believe Indivior is more favorable than Benchmark.

Profitability

This table compares Indivior and Benchmark's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Indivior and Benchmark's gross revenue, earnings per share (EPS) and valuation.

Benchmark is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Summary

Indivior beats Benchmark on 4 of the 6 factors compared between the two stocks.

Oxford Biomedica (LON:OXB) and Benchmark (LON:BMK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and target prices for Oxford Biomedica and Benchmark, as reported by MarketBeat.com.

Oxford Biomedica currently has a consensus price target of GBX 926.67, suggesting a potential downside of 10.03%. Given Oxford Biomedica's higher probable upside, research analysts clearly believe Oxford Biomedica is more favorable than Benchmark.

Profitability

This table compares Oxford Biomedica and Benchmark's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Oxford Biomedica and Benchmark's revenue, earnings per share (EPS) and valuation.

Oxford Biomedica is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

Benchmark (LON:BMK) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Benchmark and MaxCyte, as reported by MarketBeat.

Earnings & Valuation

This table compares Benchmark and MaxCyte's revenue, earnings per share and valuation.

MaxCyte is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Benchmark and MaxCyte's net margins, return on equity and return on assets.

Summary

Benchmark beats MaxCyte on 3 of the 4 factors compared between the two stocks.

Spire Healthcare Group (LON:SPI) and Benchmark (LON:BMK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings & Valuation

This table compares Spire Healthcare Group and Benchmark's top-line revenue, earnings per share and valuation.

Benchmark is trading at a lower price-to-earnings ratio than Spire Healthcare Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Spire Healthcare Group and Benchmark, as provided by MarketBeat.

Spire Healthcare Group presently has a consensus price target of GBX 136.33, suggesting a potential downside of 21.74%. Given Spire Healthcare Group's higher probable upside, equities analysts clearly believe Spire Healthcare Group is more favorable than Benchmark.

Profitability

This table compares Spire Healthcare Group and Benchmark's net margins, return on equity and return on assets.

Summary

Spire Healthcare Group beats Benchmark on 4 of the 6 factors compared between the two stocks.